Bone Abstracts

Objective: The purpose of this study was to compare the efficacy of raloxifene (RLX) 60 mg daily, vitamin D (VD) 200 IU daily, and alendronate (ALN) 35 mg once weekly on bone mineral density (BMD) of lumbar spine (L) and total femur (F) in postmenopausal women with osteoporosis, and the effects of the osteoporosis risk factors on BMDs and these treatments.Design and methods: The subjects were 242 postmenopausal Japanese women aged 48–87 years (mean ...

Objectives: Osteopenia is a complication of childhood cancer treatment but it is unknown to which extend this occurs in adult survivors, and which subgroups are at risk. We examined bone mineral density (BMD) and assed the relative importance of potential determinants of low BMD in very long-term adult survivors of childhood cancer.Methods: The single-center cohort study included 410 adult CCSs (median age at diagnosis: 6.6 years (range: 0–17 years)...

Introduction: Effective screening for vitamin D (Vit-D) insufficiency is desirable. Pigmentation of unexposed (constitutive) skin and exposed (facultative) skin can be measured with skin colourimetry to assess dermal capability in synthesizing Vit-D and degree of sunlight exposure respectively. This study aimed at evaluating whether skin colourimetry could be used to screen Vit-D insufficiency among adolescents.Methods: 240 healthy adolescents (mean age=...

The relationship between BMD T-score and FX risk has not been established in patients receiving osteoporosis therapy. In the FREEDOM Extension study, continuous DMAb therapy for up to 10 years increased BMD levels with no therapeutic plateau at lumbar spine or TH [Bone et al, ASBMR 2015]. Such improvements would only be meaningful if associated with FX reductions. We investigated the relationship between TH BMD T-score and NVFX in women who received DMAb during FREEDOM and tho...

Objectives: We evaluated the efficacy and safety of intravenous zoledronic acid (IV ZA) in children with glucocorticoid-induced osteoporosis (GIOP) through a randomized, placebo (PBO)-controlled trial.Methods: In this multi-national Phase 3 trial (NCT00799266), children 5–17 years of age with GIOP and low-trauma vertebral fractures (VF) were randomized 1:1 to IV ZA 0.05 mg/kg or IV PBO every six months for one year. Changes in lumbar spine areal bon...

Age is one of the most important factors that influence bone condition. At the age of 40–45 years for women (F) and 50 years for men (M) processes of bone formation and resorption are balanced, then bone resorption predominates.We examined 103 M (20–78 years) and 360 F (20–87 years), residing in the Republic of Karelia. Densitometry was performed for all patients to assess age-related changes in bone mineral density (BMD) at the lumbar spi...

Mechanosenstitive osteocytes in bone supress the local production of sclerostin in response to mechanical loading, to increase osteoblast differentiation and bone mass. In addition, sclerostin is secreted from osteocytes into the circulation. Serum sclerostin has been shown to correlate with osteoporosis and low bone mass, however there is limited evidence by which to determine whether serum sclerostin is acting either a biomark...

Objectives: Children who fracture have lower bone mineral density (BMD) measured by dual energy X-ray absorptiometry (DXA) than children who do not sustain fractures, but there is little data on bone microarchitecture in relation to childhood fracture. We assessed tibia microarchitecture using high resolution peripheral quantitative computed tomography (HR-pQCT) in children with recent fracture and those without a history of fracture.Methods: Children ag...

The aim of the study was to evaluate the peculiarities of body composition in postmenopausal women depending on bone mineral density (BMD).Materials and methods: We’ve examined 8882 women aged 20–89 years (mean age – 56.7±0.14 years; mean height – 162.5±0.07 cm; mean weight – 73.5±0.16 kg). Anthropometric measures were performed in 80 postmenopausal women aged 40–82 years (mean age – 63.53±1.08 years...

Biographical DetailsDr Frank Rauch obtained his MD degree from the Technical University of Munich, Germany, and trained as a pediatrician at the Children’s Hospital of Cologne University, Germany. Since 2001 Dr F Rauch has been a clinician-scientist at the Shriners Hospital for Children and is currently a Professor of Pediatrics at McGill University, Montreal, Canada. His clinical an...